GLMD

Business Context and Reporting Period

Company: Galmed Pharmaceuticals Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Three months ended March 31, 2025
Filing Date: May 22, 2025

Galmed is a biopharmaceutical company focused on developing Aramchol for liver disease, oncological indications, and cardiometabolic conditions. The company has no approved products and has not generated product sales revenue. Operations are funded primarily through equity financings.

Key Financial Metrics

*Q1 2024 per share data retroactively adjusted for reverse stock splits.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased by approximately 13% ($0.2 million) compared to Q1 2024, driven primarily by a 17% reduction in General and Administrative (G&A) expenses due to lower professional service fees.
• Operating Expenses: Total operating expenses declined from $1.4 million to $1.3 million. Research and Development (R&D) expenses remained flat at approximately $0.6 million.
• Capital Structure: Significant share issuance occurred during the quarter. The company issued 541,996 shares via an At-The-Market (ATM) program and 7,891 commitment shares under a Standby Equity Purchase Agreement (SEPA). Total shares outstanding increased from 1.66 million (Dec 31, 2024) to 2.26 million (Mar 31, 2025).
• Liquidity: Cash and cash equivalents increased slightly from $4.7 million to $4.8 million. Total liquid assets (including short-term deposits and marketable securities) grew to approximately $15.9 million.

Outlook, Risks, and Management Commentary

• Liquidity Outlook: Management estimates current cash resources will support operations for more than 12 months from the filing date. However, substantial additional capital is required to advance clinical trials and commercialization.
• Financing Activities:
  • SEPA: Entered into an agreement with YA II PN, LTD. for up to $20.0 million (amended from $10.0 million). As of March 31, 2025, the company raised approximately $5.1 million under this facility.
  • ATM Program: Entered into a Sales Agreement with JonesTrading for up to $8.1 million. Approximately $1.5 million was raised by March 31, 2025. Subsequent to the period end, an additional $5.1 million was raised.
• Key Risks:
  • Geopolitical Instability: The company's headquarters and operations are in Israel. Ongoing conflicts (Hamas, Hezbollah, Houthi attacks) pose risks to employee availability, supply chains, and business continuity. While no employees are currently in active duty, service providers may be affected.
  • Development Risk: No products are approved. Success depends on clinical trial outcomes and regulatory approvals (FDA/EMA), which are uncertain and costly.
  • Capital Requirements: Failure to secure additional financing could force the company to delay or eliminate R&D programs.

Investor Verification Checklist

• Cash Runway: Verify the 12-month liquidity estimate against current burn rates and potential delays in clinical milestones.
• Dilution Impact: Assess the impact of recent share issuances (SEPA and ATM) on existing shareholder ownership and future dilution potential.
• Geopolitical Exposure: Review the company's business continuity plan regarding the security situation in Israel and potential disruptions to clinical trials or vendor relationships.
• Revenue Timeline: Confirm the timeline for potential licensing revenue or product commercialization, as the company currently has zero product revenue.
• Subsequent Events: Note the significant capital raise ($5.1 million) under the ATM program occurring after March 31, 2025, which improves liquidity but increases share count.